Medicinal composition for resisting thrombotic diseases, preparation method thereof and application thereof

A technique for thrombotic diseases and compositions, applied in the field of pharmaceutical compositions for antithrombotic diseases and its preparation and application, capable of solving undiscovered problems, reducing bleeding or bleeding tendency, and preventing or treating thrombotic diseases Effect

Active Publication Date: 2010-03-03
BEIJING SIHUAN PHARMA
View PDF2 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] No antithrombotic drug based on timosaponin AIII combined with timosaponin BII has been found so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for resisting thrombotic diseases, preparation method thereof and application thereof
  • Medicinal composition for resisting thrombotic diseases, preparation method thereof and application thereof
  • Medicinal composition for resisting thrombotic diseases, preparation method thereof and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] The pharmaceutical composition of the present invention is to mouse tail vein bleeding time and the effect of tail vein collagen injection on lethal time

[0053] 1. Experimental materials and methods

[0054] 1 Experimental materials

[0055] Timosaponin AIII and BII monomer compounds were prepared according to known methods (Acta Pharmacologica Sinica 1996; 31(4): 271-277; Chem Pharm Bull, 1963, 11: 1221), and the purity of these two compounds was greater than 98.5% ; Wistar rats, male, weighing 280-320 grams, Kunming mice, male, weighing 22-24 grams, provided by the Animal Breeding Center of the Academy of Military Medical Sciences. Epinephrine was purchased from Beijing Yongkang Pharmaceutical Co., Ltd. Collagen is rat tail collagen self-made in our laboratory. PBS was purchased from Tianwei Times Company. Heparin was purchased from Sigma, and normal saline was purchased from Shandong Linzi Pharmaceutical Factory. Aspirin, Shijiazhuang Pharmaceutical Group ...

Embodiment 2

[0097] Embodiment 2 The pharmaceutical composition of the present invention inhibits in vitro Study on Platelet Aggregation

[0098] 1. Materials and methods

[0099] 1. Experimental materials

[0100] Wistar rats, male, weighing 280-320g, big-eared white rabbits, female, weighing 2-2.5Kg, macaques, male, weighing 5-7Kg, were all provided by the Animal Breeding Center of the Academy of Military Medical Sciences. Human platelets were provided by Beijing Blood Center. The pharmaceutical composition of the present invention, which is a white powder, was prepared according to the method described in Example 15. Adenosine diphosphate (ADP), arachidonic acid (AA), and dimethyl sulfoxide (DMSO) were all products of Sigma; Ristocetin and epinephrine were purchased from Biopool.

[0101] 2. Experimental method

[0102] 2.1 Blood collection

[0103] Male Wistar rats were anesthetized by intraperitoneal injection of 2% pentobarbital sodium (30-40mg / kg), and blood was collected f...

Embodiment 3

[0141] Embodiment 3. In vivo administration of the pharmaceutical composition of the present invention Inhibition of Thrombosis

[0142] 1. Materials and methods

[0143] 1. Experimental materials

[0144] Wistar rats, male, weighing 280-320 g, were provided by the Experimental Animal Center of the Academy of Military Medical Sciences. The timosaponin BII and AIII compositions were prepared according to the method described in Example 5. Heparin was purchased from Sigma, USA. Normal saline was purchased from Beijing Double Crane Pharmaceutical Co., Ltd. Aspirin, Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. Clotting time (PT, TT and APTT) kits were purchased from Shanghai Sun Biotechnology Company.

[0145] 2. Experimental method

[0146] 2.1 Animal grouping

[0147] Wistar rats are randomly divided into five groups, i.e. blank control group, aspirin 40mg / kg group, pharmaceutical composition 10mg / kg, 20mg / kg, 40mg / kg group of the present invention,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicinal composition for resisting thrombotic diseases, a preparation method thereof and application thereof. The medicinal composition mainly comprises timosaponin AIII and timosaponin B II, optionally comprises pharmaceutic adjuvants, and is characterized in that the content of the timosaponin AIII is more than or equal to that of the timosaponin B II. The invention also relates to the application of the composition of the timosaponin AIII and the timosaponin B II in the preparation of medicaments or products for preventing or treating the thrombotic diseases. Themedicinal composition takes effects of preventing or treating the thrombotic diseases, and simultaneously relieves the bleeding or bleeding tendency of patients.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for antithrombotic diseases and its preparation method and application, in particular to a pharmaceutical composition comprising timosaponin AIII and timosaponin BII, its preparation method and its preparation method for Use in medicines for preventing or treating thrombotic diseases. Background technique [0002] The adhesion, aggregation, and release reactions of platelets lead to thrombus formation. Thrombosis is the main cause of many human cardiovascular and cerebrovascular diseases such as myocardial infarction and stroke, and it is also an aggravating factor for some important diseases such as diabetes and vasculitis. Antithrombotic therapy is one of the main treatment measures for these diseases. Inhibition of platelet aggregation, anticoagulation and thrombolysis are the three major themes in the treatment of thrombotic diseases, among which anti-platelet aggregation therapy is th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/58A61P7/02
Inventor 马百平从玉文车冯升康利平高月谭大维熊呈琦赵阳邹鹏夏中宁
Owner BEIJING SIHUAN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap